Finance entity
All 1 tracked stories fall under one category: earnings. Pfizer is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. At 5, the average consequence score sits below the same-window beat average of 6.4. They are less corroborated than the beat average, carrying 2 original sources each against 2.5 for the same window.
Last mentioned: Feb 23, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: earnings. Pfizer is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. At 5, the average consequence score sits below the same-window beat average of 6.4. They are less corroborated than the beat average, carrying 2 original sources each against 2.5 for the same window. ORIC Pharmaceuticals appears in 1 tracked Finance story from February 23, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 57 Finance stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering ORIC Pharmaceuticals. Shared-story counts are live from our verified record — not editorial picks.
Tarsus Pharmaceuticals and ORIC Pharmaceuticals reported fourth-quarter 2025 results, highlighting a pivotal shift toward commercial scaling and clinical data maturation. While Tarsus focuses on the rapid adoption of XDEMVY, ORIC is advancing its oncology pipeline with key data readouts expected in 2026.
ORIC Pharmaceuticals is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
